[go: up one dir, main page]

DK1868579T3 - Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer - Google Patents

Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer

Info

Publication number
DK1868579T3
DK1868579T3 DK06707141.5T DK06707141T DK1868579T3 DK 1868579 T3 DK1868579 T3 DK 1868579T3 DK 06707141 T DK06707141 T DK 06707141T DK 1868579 T3 DK1868579 T3 DK 1868579T3
Authority
DK
Denmark
Prior art keywords
carboxyaryl
omega
sun
cancer
treatment
Prior art date
Application number
DK06707141.5T
Other languages
English (en)
Inventor
Fritz Schueckler
Axel Wollenschlaeger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36507604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1868579(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1868579T3 publication Critical patent/DK1868579T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06707141.5T 2005-03-07 2006-02-22 Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer DK1868579T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65882705P 2005-03-07 2005-03-07
PCT/EP2006/001574 WO2006094626A1 (en) 2005-03-07 2006-02-22 Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK1868579T3 true DK1868579T3 (da) 2011-01-10

Family

ID=36507604

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06707141.5T DK1868579T3 (da) 2005-03-07 2006-02-22 Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer

Country Status (38)

Country Link
US (2) US9737488B2 (da)
EP (1) EP1868579B1 (da)
JP (1) JP5304241B2 (da)
KR (1) KR101335932B1 (da)
CN (2) CN104688697A (da)
AR (1) AR054234A1 (da)
AT (1) ATE482693T1 (da)
AU (1) AU2006222365B2 (da)
BR (1) BRPI0608840B8 (da)
CA (1) CA2601955C (da)
CR (1) CR9348A (da)
CU (1) CU23821A3 (da)
CY (1) CY1111065T1 (da)
DE (1) DE602006017188D1 (da)
DK (1) DK1868579T3 (da)
DO (1) DOP2006000057A (da)
ES (1) ES2351612T3 (da)
GT (1) GT200600096A (da)
HK (1) HK1209620A1 (da)
HN (1) HN2006009702A (da)
HR (1) HRP20100674T1 (da)
IL (1) IL185517A (da)
MA (1) MA29378B1 (da)
MX (1) MX2007010856A (da)
MY (1) MY162319A (da)
NO (1) NO343834B1 (da)
NZ (1) NZ561178A (da)
PE (1) PE20061345A1 (da)
PL (1) PL1868579T3 (da)
PT (1) PT1868579E (da)
SG (1) SG160364A1 (da)
SI (1) SI1868579T1 (da)
TN (1) TNSN07341A1 (da)
TW (1) TWI324928B (da)
UA (1) UA93673C2 (da)
UY (1) UY29410A1 (da)
WO (1) WO2006094626A1 (da)
ZA (1) ZA200707638B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
PL1797038T3 (pl) * 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
EP1968589A2 (en) * 2005-10-31 2008-09-17 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
US8846628B2 (en) 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010142678A2 (en) * 2009-06-12 2010-12-16 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
PL2528899T3 (pl) * 2010-01-29 2015-02-27 Ranbaxy Laboratories Ltd Solwat sorafenibu z dimetylosulfotlenkiem
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
PL2806860T3 (pl) 2012-01-23 2023-09-11 Sandoz Ag Kompozycja farmaceutyczna zawierająca krystaliczny tosylan sorafenibu
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
EP3193877A4 (en) 2014-08-07 2018-04-04 Pharmacyclics LLC Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
BR112017022867B1 (pt) * 2015-05-14 2022-07-19 Dupont Nutrition Usa, Inc Método para fabricaçao de celulose microcristalina
WO2017159585A1 (ja) * 2016-03-14 2017-09-21 参天製薬株式会社 メグルミン又はその塩からなる防腐剤
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
CN106344530B (zh) * 2016-09-30 2019-03-19 京津冀联创药物研究（北京）有限公司 一种索拉非尼组合物及其制备方法
KR102693361B1 (ko) 2017-05-26 2024-08-09 브루인 바이오사이언시스, 인크. 화학색전제
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en) * 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Solid dosage form containing sorafenib tosylate
BR112021008516A2 (pt) 2018-11-01 2021-09-14 Syros Pharmaceuticals, Inc. Inibidores de quinase 7 dependente de ciclina (cdk 7)
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125359A (en) * 1964-03-17 Push-pull breakaway coupling
NL121140C (da) * 1961-11-08
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
JPH11511130A (ja) 1995-07-25 1999-09-28 スミスクライン・ビーチャム・コーポレイション ＣｏＡ−非依存性トランスアシラーゼの阻害およびアポトーシス
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
DE1019040T1 (de) 1997-05-23 2001-02-08 Bayer Corp., West Haven Hemmung von p38 kinase aktivität durch arylharnstoff
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP0986382B1 (en) 1997-05-23 2008-06-25 Bayer Pharmaceuticals Corporation Raf kinase inhibitors
HU227711B1 (en) 1997-12-22 2011-12-28 Bayer Healthcare Llc Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas and pharmaceutical compositions containing them
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
AU1939999A (en) 1997-12-22 1999-07-12 Bayer Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
PL341356A1 (en) 1997-12-22 2001-04-09 Bayer Ag Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20030087849A1 (en) 2001-07-03 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of HKR1 expression
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ATE253051T1 (de) 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
PT1309315E (pt) * 2000-08-18 2006-09-29 Pharmacia Corp Formulacao oral de desintegracao rapida de valdecoxib
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UY27225A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
DE60218445T2 (de) 2001-04-20 2007-11-29 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
US20030207914A1 (en) 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2400070T3 (es) 2001-12-03 2013-04-05 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
US20080108672A1 (en) 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
JP4594925B2 (ja) 2003-02-28 2010-12-08 ニッポネックス インコーポレイテッド 増殖亢進性、血管新生性及び炎症性疾患の治療に有用な２−オキソ−１，３，５−パーヒドロトリアザピン誘導体
EP1608639A2 (en) 2003-02-28 2005-12-28 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP4927533B2 (ja) 2003-02-28 2012-05-09 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な置換ピリジン誘導体
US6896863B2 (en) 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
WO2005009367A2 (en) 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
MXPA06003163A (es) 2003-09-23 2006-06-05 Novartis Ag Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
US7552093B2 (en) * 2003-12-04 2009-06-23 Black Duck Software, Inc. Resolving license dependencies for aggregations of legally-protectable content
CA2548394A1 (en) 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
CA2571555A1 (en) 2004-06-22 2006-01-05 Pfizer Products Inc. Diazabicyclic histamine-3 receptor antagonists
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006026501A1 (en) 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
PL1797038T3 (pl) 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
BRPI0515944B1 (pt) 2004-09-29 2021-11-09 Bayer Healthcare Llc Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
JP2008545670A (ja) 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
MX2007014726A (es) 2005-05-27 2008-02-14 Bayer Healthcare Ag Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
EP1937837A2 (en) 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2007047955A2 (en) 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1954272A2 (en) 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP1968589A2 (en) 2005-10-31 2008-09-17 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
BRPI0618564A2 (pt) 2005-11-02 2011-09-06 Bayer Healthcare Llc métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer
EP1946116A4 (en) 2005-11-02 2010-01-06 Bayer Healthcare Llc METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
JP5075832B2 (ja) 2005-11-10 2012-11-21 バイエル・ファルマ・アクチェンゲゼルシャフト 肺高血圧を処置するためのジアリールウレア
WO2007059155A1 (en) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
CA2629863A1 (en) 2005-11-14 2007-05-24 Scott Wilhelm Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors
AU2006315592A1 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
MX2008006979A (es) 2005-12-01 2009-01-14 Bayer Healthcare Llc Compuestos de urea utiles en el tratamiento contra el cancer.
US20090227637A1 (en) 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
EP2111401B1 (en) 2006-12-20 2011-02-16 Bayer HealthCare, LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

Also Published As

Publication number Publication date
SI1868579T1 (sl) 2011-02-28
AR054234A1 (es) 2007-06-13
CN101132779A (zh) 2008-02-27
NO20075042L (no) 2007-10-05
MA29378B1 (fr) 2008-04-01
HRP20100674T1 (hr) 2011-01-31
RU2420283C2 (ru) 2011-06-10
AU2006222365A1 (en) 2006-09-14
CU20070203A7 (es) 2010-01-22
TW200700093A (en) 2007-01-01
US20080242707A1 (en) 2008-10-02
PT1868579E (pt) 2010-12-03
GT200600096A (es) 2007-01-12
MX2007010856A (es) 2007-11-12
NO343834B1 (no) 2019-06-17
BRPI0608840B8 (pt) 2021-05-25
CA2601955C (en) 2012-07-10
EP1868579B1 (en) 2010-09-29
DOP2006000057A (es) 2006-09-30
UA93673C2 (ru) 2011-03-10
BRPI0608840A2 (pt) 2010-02-02
DE602006017188D1 (de) 2010-11-11
CN101132779B (zh) 2016-03-16
JP5304241B2 (ja) 2013-10-02
HK1118019A1 (zh) 2009-01-30
ES2351612T3 (es) 2011-02-08
US20180036249A1 (en) 2018-02-08
EP1868579A1 (en) 2007-12-26
BRPI0608840B1 (pt) 2020-04-14
CN104688697A (zh) 2015-06-10
ZA200707638B (en) 2009-08-26
NZ561178A (en) 2010-11-26
UY29410A1 (es) 2006-10-31
WO2006094626A1 (en) 2006-09-14
JP2008531741A (ja) 2008-08-14
RU2007136896A (ru) 2009-04-20
CU23821A3 (es) 2012-06-21
ATE482693T1 (de) 2010-10-15
PE20061345A1 (es) 2007-01-28
KR20070111513A (ko) 2007-11-21
CY1111065T1 (el) 2015-06-11
AU2006222365B2 (en) 2011-07-14
IL185517A (en) 2016-05-31
IL185517A0 (en) 2008-01-06
US9737488B2 (en) 2017-08-22
HN2006009702A (es) 2010-06-08
SG160364A1 (en) 2010-04-29
KR101335932B1 (ko) 2013-12-04
CR9348A (es) 2008-02-13
MY162319A (en) 2017-05-31
HK1209620A1 (en) 2016-04-08
PL1868579T3 (pl) 2011-03-31
TNSN07341A1 (en) 2008-12-31
CA2601955A1 (en) 2006-09-14
TWI324928B (en) 2010-05-21

Similar Documents

Publication Publication Date Title
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2139517T3 (da) Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
DK2063881T3 (da) Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
EP1930376A4 (en) POLYMERIZABLE COMPOSITION
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme